South America Prostate Cancer Nuclear Medicine Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – by Type (PET and SPECT), PET Product (F-18, C-11, and Ga68-PSMA), and End User (Hospitals, Clinics, and Others)
The SAM prostate cancer nuclear medicine market is expected to grow from US$ 30.64 million in 2022 to US$ 52.63 million by 2028; it is estimated to grow at a CAGR of 9.4% from 2022 to 2028.
The rise in PSA levels increases the risk of prostate cancer. PSA levels in the blood are measured in nanograms per milliliter (ng/mL) units. There is no definitive cutoff point that can determine if a man has prostate cancer or not. When assessing whether a man needs further testing, many doctors choose a PSA cutoff of 4 ng/mL or above, while others may advocate starting at a lower level, such as 2.5 or 3. Therefore, testing PSA levels in a man's blood can detect prostate cancer early. Also, a digital rectal exam (DRE) is another approach to detecting prostate cancer. The doctor uses a gloved, lubricated finger to feel the prostate gland during the exam. Regular screening with a well-validated biomarker could lead to quicker detection of localized disease. Furthermore, distinguishing between low-grade and high-grade disease is critical to avoid unnecessary biopsies, undertreatment of serious disease, and overtreatment of indolent disease.
With the new features and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the SAM prostate cancer nuclear medicine market. The SAM prostate cancer nuclear medicine market is expected to grow at a good CAGR during the forecast period.
SAM Prostate cancer nuclear medicine Market Revenue and Forecast to 2028 (US$ Million)
SAM Prostate cancer nuclear medicine Market Segmentation
The SAM prostate cancer nuclear medicine market is segmented into type, PET product, end user, and country. Based on type, the SAM prostate cancer nuclear medicine market is divided into PET and SPECT. The PET dominated the SAM prostate cancer nuclear medicine market in 2022. Based on PET product, the SAM prostate cancer nuclear medicine market is categorized into F-18, C-11, and Ga68-PSMA. The F-18 segment dominated the SAM prostate cancer nuclear medicine market in 2022. Based on end user, the SAM prostate cancer nuclear medicine market is categorized into hospitals, clinics, and others. The hospitals segment dominated the SAM prostate cancer nuclear medicine market in 2022. Based on country, the SAM prostate cancer nuclear medicine market is segmented into Brazil, Argentina, and the rest of SAM. The Brazil segment dominated the SAM prostate cancer nuclear medicine market in 2022.
ImaginAb; Curium; ABX advanced biochemical compounds GmbH; Telix Pharmaceuticals Ltd; Novartis AG; and Lantheus Medical Imaging, Inc. by Altair are among the leading companies in the SAM prostate cancer nuclear medicine market.
1. Introduction
1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
1.3.1 SAM Prostate Cancer Nuclear Medicine Diagnostics Market – By Type
1.3.2 SAM Prostate Cancer Nuclear Medicine Diagnostics Market – By PET Product
1.3.3 SAM Prostate Cancer Nuclear Medicine Diagnostics Market – By End User
1.3.4 SAM Prostate Cancer Nuclear Medicine Diagnostics Market – By Country
2. Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. SAM Prostate Cancer Nuclear Medicine Diagnostics Market – Market Landscape
4.1 Overview
4.2 PEST Analysis
4.2.1 SAM PEST Analysis
4.3 Experts Opinion
5. SAM Prostate Cancer Nuclear Medicine Diagnostics Market– Key Market Dynamics
5.1 Market Drivers
5.1.1 Rising Prevalence of Prostate Cancer
5.1.2 Surging Demand for Early and Precise Diagnosis of Prostate Cancer
5.2 Market Restraints
5.2.1 High Cost Related to the Prostate Cancer Diagnostics and Treatment
5.3 Market Opportunities
5.3.1 Growing Use of Radiopharmaceuticals in Prostate Cancer
5.4 Future Trends
5.4.1 Increasing Research Activities for Development of Innovative Imaging Agents
5.5 Impact Analysis
6. Prostate Cancer Nuclear Medicine Diagnostics Market– SAM Analysis
6.1 SAM Prostate Cancer Nuclear Medicine Diagnostics Market Revenue Forecast and Analysis
7. SAM Prostate Cancer Nuclear Medicine Diagnostics Market Analysis – By Type
7.1 Overview
7.2 Prostate Cancer Nuclear Medicine Diagnostics Market, By Type, 2022 & 2028 (%)
7.3 SPECT
7.3.1 Overview
7.3.2 SPECT: Prostate Cancer Nuclear Medicine Diagnostics Market Revenue and Forecasts to 2028 (US$ Million)
7.4 PET
7.4.1 Overview
7.4.2 PET: Prostate Cancer Nuclear Medicine Diagnostics Market Revenue and Forecasts to 2028 (US$ Million)
8. SAM Prostate Cancer Nuclear Medicine Diagnostics Market Analysis – By PET Product
8.1 Overview
8.2 SAM Prostate Cancer Nuclear Medicine Diagnostics Market, By PET Product, 2022 & 2028 (%)
8.3 F-18
8.3.1 Overview
8.3.2 F-18: Prostate Cancer Nuclear Medicine Diagnostics Market Revenue and Forecast to 2028 (US$ Million)
8.4 C-11
8.4.1 Overview
8.4.2 C-11: Prostate Cancer Nuclear Medicine Diagnostics Market Revenue and Forecast to 2028 (US$ Million)
8.5 GA 68 PSMA
8.5.1 Overview
8.5.2 GA 68 PSMA: Prostate Cancer Nuclear Medicine Diagnostics Market Revenue and Forecast to 2028 (US$ Million)
9. SAM Prostate Cancer Nuclear Medicine Diagnostics Market – By End User
9.1 Overview
9.2 SAM Prostate Cancer Nuclear Medicine Diagnostics Market Share by End User- 2022 & 2028 (%)
9.3 Hospitals
9.3.1 Overview
9.3.2 Hospitals: Prostate Cancer Nuclear Medicine Diagnostics Market Revenue and Forecast to 2028 (US$ Million)
9.4 Clinics
9.4.1 Overview
9.4.2 Clinics: Prostate Cancer Nuclear Medicine Diagnostics Market Revenue and Forecast to 2028 (US$ Million)
9.5 Others
9.5.1 Overview
9.5.2 Others: Prostate Cancer Nuclear Medicine Diagnostics Market Revenue and Forecast to 2028 (US$ Million)
10. SAM Prostate Cancer Nuclear Medicine Diagnostics Market – By Country Analysis
10.1 SAM Prostate Cancer Nuclear Medicine Diagnostics Market Revenue and Forecasts To 2028
10.1.1 Overview
10.1.2 SAM: Prostate Cancer Nuclear Medicine Diagnostics Market, by Country, 2022 & 2028 (%)
10.1.2.1 Brazil: Prostate Cancer Nuclear Medicine Diagnostics Market – Revenue and Forecast to 2028 (USD Million)
10.1.2.1.1 Overview
10.1.2.1.2 Brazil: Prostate Cancer Nuclear Medicine Diagnostics Market – Revenue and Forecast to 2028 (USD Million)
10.1.2.1.3 Brazil: Prostate Cancer Nuclear Medicine Diagnostics Market, by Type, 2019–2028 (USD Million)
10.1.2.1.4 Brazil: Prostate Cancer Nuclear Medicine Diagnostics Market, by PET Product, 2019–2028 (USD Million)
10.1.2.1.5 Brazil: Prostate Cancer Nuclear Medicine Diagnostics Market, by End User, 2019–2028 (USD Million)
10.1.2.2 Argentina: Prostate Cancer Nuclear Medicine Diagnostics Market – Revenue and Forecast to 2028 (USD Million)
10.1.2.2.1 Overview
10.1.2.2.2 Argentina: Prostate Cancer Nuclear Medicine Diagnostics Market – Revenue and Forecast to 2028 (USD Million)
10.1.2.2.3 Argentina: Prostate Cancer Nuclear Medicine Diagnostics Market, by Type, 2019–2028 (USD Million)
10.1.2.2.4 Argentina: Prostate Cancer Nuclear Medicine Diagnostics Market, by PET Product, 2019–2028 (USD Million)
10.1.2.2.5 Argentina: Prostate Cancer Nuclear Medicine Diagnostics Market, by End User, 2019–2028 (USD Million)
10.1.2.3 Rest of South and Central America: Prostate Cancer Nuclear Medicine Diagnostics Market – Revenue and Forecast to 2028 (USD Million)
10.1.2.3.1 Overview
10.1.2.3.2 Rest of SAM: Prostate Cancer Nuclear Medicine Diagnostics Market – Revenue and Forecast to 2028 (USD Million)
10.1.2.3.3 Rest of SAM: Prostate Cancer Nuclear Medicine Diagnostics Market, by Type, 2019–2028 (USD Million)
10.1.2.3.4 Rest of SAM: Prostate Cancer Nuclear Medicine Diagnostics Market , by PET Product, 2019–2028 (USD Million)
10.1.2.3.5 Rest of SAM: Prostate Cancer Nuclear Medicine Diagnostics Market , by End User, 2019–2028 (USD Million)
11. Company Profiles
11.1 ImaginAb
11.1.1 Key Facts
11.1.2 Business Description
11.1.3 Products and Services
11.1.4 Financial Overview
11.1.5 SWOT Analysis
11.1.6 Key Developments
11.2 Curium
11.2.1 Key Facts
11.2.2 Business Description
11.2.3 Products and Services
11.2.4 Financial Overview
11.2.5 SWOT Analysis
11.2.6 Key Developments
11.3 ABX advanced biochemical compounds GmbH
11.3.1 Key Facts
11.3.2 Business Description
11.3.3 Products and Services
11.3.4 Financial Overview
11.3.5 SWOT Analysis
11.3.6 Key Developments
11.4 Telix Pharmaceuticals Ltd.
11.4.1 Key Facts
11.4.2 Business Description
11.4.3 Products and Services
11.4.4 Financial Overview
11.4.5 SWOT Analysis
11.4.6 Key Developments
11.5 Novartis AG
11.5.1 Key Facts
11.5.2 Business Description
11.5.3 Products and Services
11.5.4 Financial Overview
11.5.5 SWOT Analysis
11.5.6 Key Developments
11.6 Lantheus Medical Imaging, Inc.
11.6.1 Key Facts
11.6.2 Business Description
11.6.3 Products and Services
11.6.4 Financial Overview
11.6.5 SWOT Analysis
11.6.6 Key Developments
12. Appendix
12.1 About The Insight Partners
12.2 Glossary of Terms
LIST OF TABLES
Table 1. Brazil: Prostate Cancer Nuclear Medicine Diagnostics Market, by Type – Revenue and Forecast to 2028 (USD Million)
Table 2. Brazil: Prostate Cancer Nuclear Medicine Diagnostics Market, by PET Product – Revenue and Forecast to 2028 (USD Million)
Table 3. Brazil: Prostate Cancer Nuclear Medicine Diagnostics Market, by End User– Revenue and Forecast to 2028 (USD Million)
Table 4. Argentina: Prostate Cancer Nuclear Medicine Diagnostics Market, by Type – Revenue and Forecast to 2028 (USD Million)
Table 5. Argentina: Prostate Cancer Nuclear Medicine Diagnostics Market, by PET Product – Revenue and Forecast to 2028 (USD Million)
Table 6. Argentina: Prostate Cancer Nuclear Medicine Diagnostics Market, by End User– Revenue and Forecast to 2028 (USD Million)
Table 7. Rest of SAM: Prostate Cancer Nuclear Medicine Diagnostics Market, by Type – Revenue and Forecast to 2028 (USD Million)
Table 8. Rest of South and Central America: Prostate Cancer Nuclear Medicine Diagnostics Market, by PET Product – Revenue and Forecast to 2028 (USD Million)
Table 9. Rest of South and Central America: Prostate Cancer Nuclear Medicine Diagnostics Market, by End User– Revenue and Forecast to 2028 (USD Million)
Table 10. Glossary of Terms, Prostate Cancer Nuclear Medicine Diagnostics Market
LIST OF FIGURES
Figure 1. SAM Prostate Cancer Nuclear Medicine Diagnostics Market Segmentation
Figure 2. SAM Prostate Cancer Nuclear Medicine Diagnostics Market, By Country
Figure 3. SAM Prostate Cancer Nuclear Medicine Diagnostics Market Overview
Figure 4. PET Segment Held Largest Share of Type Segment in Prostate Cancer Nuclear Medicine Diagnostics Market
Figure 5. Brazil is Expected to Show Remarkable Growth During the Forecast Period
Figure 6. SAM: PEST Analysis
Figure 7. SAM Experts Opinion
Figure 8. SAM Prostate Cancer Nuclear Medicine Diagnostics Market Impact Analysis of Drivers and Restraints
Figure 9. SAM Prostate Cancer Nuclear Medicine Diagnostics Market– Revenue Forecast and Analysis – 2022 - 2028
Figure 10. Prostate Cancer Nuclear Medicine Diagnostics Market, by Type, 2022 & 2028 (%)
Figure 11. SAM SPECT: Prostate Cancer Nuclear Medicine Diagnostics Market Revenue and Forecasts to 2028 (US$ Million)
Figure 12. SAM PET: Prostate Cancer Nuclear Medicine Diagnostics Market Revenue and Forecasts to 2028 (US$ Million)
Figure 13. SAM Prostate Cancer Nuclear Medicine Diagnostics Market, by PET Product, 2022 & 2028 (%)
Figure 14. SAM F-18: Prostate Cancer Nuclear Medicine Diagnostics Market Revenue and Forecasts To 2028 (US$ Million)
Figure 15. SAM C-11: Prostate Cancer Nuclear Medicine Diagnostics Market Revenue and Forecasts To 2028 (US$ Million)
Figure 16. SAM GA 68 PSMA: Prostate Cancer Nuclear Medicine Diagnostics Market Revenue and Forecasts To 2028 (US$ Million)
Figure 17. SAM Prostate Cancer Nuclear Medicine Diagnostics Market Share by End User - 2022 & 2028 (%)
Figure 18. SAM Hospitals: Prostate Cancer Nuclear Medicine Diagnostics Market Revenue and Forecasts To 2028 (US$ Million)
Figure 19. SAM Clinics: Prostate Cancer Nuclear Medicine Diagnostics Market Revenue and Forecasts To 2028 (US$ Million)
Figure 20. SAM Others: Prostate Cancer Nuclear Medicine Diagnostics Market Revenue and Forecasts To 2028 (US$ Million)
Figure 21. SAM: Prostate Cancer Nuclear Medicine Diagnostics Market, by Key Country – Revenue (2022) (USD Million)
Figure 22. SAM: Prostate Cancer Nuclear Medicine Diagnostics Market, by Country, 2022 & 2028 (%)
Figure 23. Brazil: Prostate Cancer Nuclear Medicine Diagnostics Market – Revenue and Forecast to 2028 (USD Million)
Figure 24. Argentina: Prostate Cancer Nuclear Medicine Diagnostics Market – Revenue and Forecast to 2028 (USD Million)
Figure 25. Rest of SAM: Prostate Cancer Nuclear Medicine Diagnostics Market – Revenue and Forecast to 2028 (USD Million)
- ImaginAb
- Curium
- ABX advanced biochemical compounds GmbH
- Telix Pharmaceuticals Ltd
- Novartis AG
- Lantheus Medical Imaging, Inc.
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the SAM prostate cancer nuclear medicine market.
- Highlights key business priorities in order to assist companies to realign their business strategies
- The key findings and recommendations highlight crucial progressive industry trends in the SAM prostate cancer nuclear medicine market, thereby allowing players across the value chain to develop effective long-term strategies
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
- Scrutinize in-depth SAM market trends and outlook coupled with the factors driving the SAM prostate cancer nuclear medicine market, as well as those hindering it
- Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution